11 December 2024
Kirkland Advises Crown Laboratories on Amended Merger Agreement with Revance
Advising firms
Deal team
25 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Marshall Shaffer | Kirkland & Ellis | Not stated | corporate | Not stated |
| Ed Lee | Kirkland & Ellis | Not stated | corporate | Not stated |
| Josh Kogan | Kirkland & Ellis | Not stated | corporate | Not stated |
| Andrew Norwich | Kirkland & Ellis | Not stated | corporate | Not stated |
| Monica Ruiz | Kirkland & Ellis | Not stated | corporate | Not stated |
| Matthew Burner | Kirkland & Ellis | Not stated | corporate | Not stated |
| Jordan Murray | Kirkland & Ellis | Not stated | investment funds | Not stated |
| Juliet Anderson | Kirkland & Ellis | Not stated | investment funds | Not stated |
| Justin Samson | Kirkland & Ellis | Not stated | investment funds | Not stated |
| Chris Stoj | Kirkland & Ellis | Not stated | investment funds | Not stated |
| Jason Kanner | Kirkland & Ellis | Not stated | debt finance | Not stated |
| Chad Davis | Kirkland & Ellis | Not stated | debt finance | Not stated |
| Angela Hagerman | Kirkland & Ellis | Not stated | debt finance | Not stated |
| Kaitlin Schock | Kirkland & Ellis | Not stated | debt finance | Not stated |
| Daly Brower | Kirkland & Ellis | Not stated | debt finance | Not stated |
| Scott Price | Kirkland & Ellis | Not stated | executive compensation | Not stated |
| Anthony Ji | Kirkland & Ellis | Not stated | executive compensation | Not stated |
| Grace Zagorskis | Kirkland & Ellis | Not stated | executive compensation | Not stated |
| Julia Danforth | Kirkland & Ellis | Not stated | capital markets | Not stated |
| Pippa Bond | Kirkland & Ellis | Not stated | capital markets | Not stated |
| Van Whiting | Kirkland & Ellis | Not stated | capital markets | Not stated |
| Sarah Yang | Kirkland & Ellis | Not stated | capital markets | Not stated |
| Elise Wang | Kirkland & Ellis | Not stated | capital markets | Not stated |
| Albert Yung Kim | Kirkland & Ellis | Not stated | antitrust & competition | Not stated |
| Mariana del Carmen Fernandez | Kirkland & Ellis | Not stated | antitrust & competition | Not stated |
Stated terms
- Stated value
- USD 3.10 ($3.10 per share)
- What the figure measures
- Per share
- Client
- Crown Laboratories, Inc.Buy-side
- Counterparties
- Revance Therapeutics, Inc. (Sell-side)